Related Experiment Video
Updated: Mar 12, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
Eric R Yoo1, Ryan B Perumpail2, George Cholankeril3
1Department of Medicine, University of Illinois College of Medicine, Chicago, IL, USA.
Abstract:
Patients with Down syndrome who received blood transfusions, likely in conjunction with cardiothoracic surgery for congenital heart disease and prior to the implementation of blood-donor screening for hepatitis C virus infection, face a substantial risk of acquiring the infection. In the past, interferon-based therapy for chronic hepatitis C infection in patients with Down syndrome was noted to have lower efficacy and potentially higher risk of adverse effects. Recently, the treatment for chronic hepatitis C has been revolutionized with the introduction of interferon-free direct acting antivirals with favorable safety, tolerability, and efficacy profile. Based on our experiences, the newly approved sofosbuvir-based direct acting antiviral therapy is well tolerated and highly efficacious in this subpopulation of hepatitis C virus infected patients with Down syndrome.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Viruses with RNA Genomes
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Retroviruses
Pharmacokinetics in Pediatric Patients: Drug Excretion

